Croatia: These 29 Drugs Face Patent Expirations and Generic Entry in 2024 - 2025
DrugPatentWatch® Estimated Loss of Exclusivity Dates in Croatia
Generic Entry Dates in Other Countries
These estimated drug patent expiration dates and generic entry opportunity dates are calculated from analysis of known patents covering drugs. Many factors can influence early or late generic entry. This information is provided as a rough estimate of generic entry potential and should not be used as an independent source. The methodology is described in this blog post.
Summary: Croatia: These 29 Drugs Face Patent Expirations and Generic Entry in 2024 - 2025
Tradename | Ingredient | Estimated Entry Opportunity Date |
---|---|---|
CREON | pancrelipase (amylase;lipase;protease) | 2025-08-15 |
OLYSIO | simeprevir sodium | 2025-07-29 |
XTANDI | enzalutamide | 2025-05-13 |
VALCHLOR | mechlorethamine hydrochloride | 2025-03-14 |
FORTEO | teriparatide recombinant human | 2024-03-30 |
INCRUSE ELLIPTA | umeclidinium bromide | 2024-04-27 |
BELEODAQ | belinostat | 2025-05-13 |
>Tradename | >Ingredient | >Estimated Entry Opportunity Date |
Details: Croatia: These 29 Drugs Face Patent Expirations and Generic Entry in 2024 - 2025
When can CREON (pancrelipase (amylase;lipase;protease)) generic drug versions launch?
Generic name: pancrelipase (amylase;lipase;protease)
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: August 15, 2025
Generic Entry Controlled by: Croatia Patent P20100269
CREON is a drug marketed by There has been litigation on patents covering CREON
See drug price trends for CREON.
The generic ingredient in CREON is pancrelipase (amylase;lipase;protease). There are six drug master file entries for this API. Additional details are available on the pancrelipase (amylase;lipase;protease) profile page.
When can OLYSIO (simeprevir sodium) generic drug versions launch?
Generic name: simeprevir sodium
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: July 29, 2025
Generic Entry Controlled by: Croatia Patent P20110237
OLYSIO is a drug marketed by Janssen Prods. There are nine patents protecting this drug.
This drug has one hundred and thirty-eight patent family members in forty-three countries.
See drug price trends for OLYSIO.
The generic ingredient in OLYSIO is simeprevir sodium. There is one drug master file entry for this API. Additional details are available on the simeprevir sodium profile page.
When can OLYSIO (simeprevir sodium) generic drug versions launch?
Generic name: simeprevir sodium
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: July 29, 2025
Generic Entry Controlled by: Croatia Patent P20151326
OLYSIO is a drug marketed by Janssen Prods. There are nine patents protecting this drug.
This drug has one hundred and thirty-eight patent family members in forty-three countries.
See drug price trends for OLYSIO.
The generic ingredient in OLYSIO is simeprevir sodium. There is one drug master file entry for this API. Additional details are available on the simeprevir sodium profile page.
When can XTANDI (enzalutamide) generic drug versions launch?
Generic name: enzalutamide
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: May 13, 2025
Generic Entry Controlled by: Croatia Patent P20120323
XTANDI is a drug marketed by Astellas. There are four patents protecting this drug and one Paragraph IV challenge. One tentatively approved generic is ready to enter the market.
This drug has one hundred and eighty-three patent family members in thirty-four countries. There has been litigation on patents covering XTANDI
See drug price trends for XTANDI.
The generic ingredient in XTANDI is enzalutamide. There are nine drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the enzalutamide profile page.
When can XTANDI (enzalutamide) generic drug versions launch?
Generic name: enzalutamide
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: May 13, 2025
Generic Entry Controlled by: Croatia Patent P20150437
XTANDI is a drug marketed by Astellas. There are four patents protecting this drug and one Paragraph IV challenge. One tentatively approved generic is ready to enter the market.
This drug has one hundred and eighty-three patent family members in thirty-four countries. There has been litigation on patents covering XTANDI
See drug price trends for XTANDI.
The generic ingredient in XTANDI is enzalutamide. There are nine drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the enzalutamide profile page.
When can VALCHLOR (mechlorethamine hydrochloride) generic drug versions launch?
Generic name: mechlorethamine hydrochloride
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: March 14, 2025
Generic Entry Controlled by: Croatia Patent P20190551
VALCHLOR is a drug marketed by Helsinn. There are six patents protecting this drug.
This drug has forty-eight patent family members in twenty countries.
See drug price trends for VALCHLOR.
The generic ingredient in VALCHLOR is mechlorethamine hydrochloride. There is one drug master file entry for this API. One supplier is listed for this generic product. Additional details are available on the mechlorethamine hydrochloride profile page.
When can VALCHLOR (mechlorethamine hydrochloride) generic drug versions launch?
Generic name: mechlorethamine hydrochloride
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: March 14, 2025
Generic Entry Controlled by: Croatia Patent P20210283
VALCHLOR is a drug marketed by Helsinn. There are six patents protecting this drug.
This drug has forty-eight patent family members in twenty countries.
See drug price trends for VALCHLOR.
The generic ingredient in VALCHLOR is mechlorethamine hydrochloride. There is one drug master file entry for this API. One supplier is listed for this generic product. Additional details are available on the mechlorethamine hydrochloride profile page.
When can FORTEO (teriparatide recombinant human) generic drug versions launch?
Generic name: teriparatide recombinant human
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: March 30, 2024
Generic Entry Controlled by: Croatia Patent P20191242
FORTEO is a drug marketed by Lilly. There is one patent protecting this drug and one Paragraph IV challenge.
This drug has thirty-seven patent family members in twenty-five countries. There has been litigation on patents covering FORTEO
See drug price trends for FORTEO.
The generic ingredient in FORTEO is teriparatide recombinant human. There are four drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the teriparatide recombinant human profile page.
When can INCRUSE ELLIPTA (umeclidinium bromide) generic drug versions launch?
Generic name: umeclidinium bromide
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: April 27, 2024
Generic Entry Controlled by: Croatia Patent P20120832
INCRUSE ELLIPTA is a drug marketed by
This drug has one hundred and seventy-seven patent family members in thirty-nine countries. There has been litigation on patents covering INCRUSE ELLIPTA
See drug price trends for INCRUSE ELLIPTA .
The generic ingredient in INCRUSE ELLIPTA is umeclidinium bromide. There are two drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the umeclidinium bromide profile page.
When can INCRUSE ELLIPTA (umeclidinium bromide) generic drug versions launch?
Generic name: umeclidinium bromide
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: April 27, 2024
Generic Entry Controlled by: Croatia Patent P20161385
INCRUSE ELLIPTA is a drug marketed by
This drug has one hundred and seventy-seven patent family members in thirty-nine countries. There has been litigation on patents covering INCRUSE ELLIPTA
See drug price trends for INCRUSE ELLIPTA .
The generic ingredient in INCRUSE ELLIPTA is umeclidinium bromide. There are two drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the umeclidinium bromide profile page.
When can BELEODAQ (belinostat) generic drug versions launch?
Generic name: belinostat
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: May 13, 2025
Generic Entry Controlled by: Croatia Patent P20120341
BELEODAQ is a drug marketed by Acrotech Biopharma. There are two patents protecting this drug and one Paragraph IV challenge.
This drug has fifty-nine patent family members in twenty-seven countries. There has been litigation on patents covering BELEODAQ
See drug price trends for BELEODAQ.
The generic ingredient in BELEODAQ is belinostat. There are five drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the belinostat profile page.
When can ISENTRESS (raltegravir potassium) generic drug versions launch?
Generic name: raltegravir potassium
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: December 03, 2024
Generic Entry Controlled by: Croatia Patent P20120066
ISENTRESS is a drug marketed by Msd Sub Merck. There are six patents protecting this drug and one Paragraph IV challenge.
This drug has one hundred and twenty-five patent family members in forty-five countries.
See drug price trends for ISENTRESS.
The generic ingredient in ISENTRESS is raltegravir potassium. There are five drug master file entries for this API. Nine suppliers are listed for this generic product. Additional details are available on the raltegravir potassium profile page.
When can HALAVEN (eribulin mesylate) generic drug versions launch?
Generic name: eribulin mesylate
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: June 03, 2024
Generic Entry Controlled by: Croatia Patent P20150543
HALAVEN is a drug marketed by Eisai Inc. There are two patents protecting this drug.
This drug has seventy-eight patent family members in twenty-six countries. There has been litigation on patents covering HALAVEN
See drug price trends for HALAVEN.
The generic ingredient in HALAVEN is eribulin mesylate. Two suppliers are listed for this generic product. Additional details are available on the eribulin mesylate profile page.
When can NUCYNTA (tapentadol hydrochloride) generic drug versions launch?
Generic name: tapentadol hydrochloride
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: June 28, 2024
Generic Entry Controlled by: Croatia Patent P20110050
NUCYNTA is a drug marketed by Collegium Pharm Inc. There are four patents protecting this drug and four Paragraph IV challenges. Three tentatively approved generics are ready to enter the market.
This drug has forty-five patent family members in twenty-six countries. There has been litigation on patents covering NUCYNTA
See drug price trends for NUCYNTA.
The generic ingredient in NUCYNTA is tapentadol hydrochloride. There are five drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the tapentadol hydrochloride profile page.
When can FYCOMPA (perampanel) generic drug versions launch?
Generic name: perampanel
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: July 06, 2024
Generic Entry Controlled by: Croatia Patent P20130363
FYCOMPA is a drug marketed by Catalyst Pharms. There are two patents protecting this drug and one Paragraph IV challenge. Three tentatively approved generics are ready to enter the market.
This drug has one hundred and one patent family members in thirty-three countries. There has been litigation on patents covering FYCOMPA
See drug price trends for FYCOMPA.
The generic ingredient in FYCOMPA is perampanel. There are five drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the perampanel profile page.
When can KOMBIGLYZE XR (metformin hydrochloride; saxagliptin hydrochloride) generic drug versions launch?
Generic name: metformin hydrochloride; saxagliptin hydrochloride
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: May 28, 2024
Generic Entry Controlled by: Croatia Patent P20160880
KOMBIGLYZE XR is a drug marketed by Astrazeneca Ab. There are two patents protecting this drug and one Paragraph IV challenge.
This drug has fifty-seven patent family members in thirty-two countries. There has been litigation on patents covering KOMBIGLYZE XR
See drug price trends for KOMBIGLYZE XR.
The generic ingredient in KOMBIGLYZE XR is metformin hydrochloride; saxagliptin hydrochloride. There are forty-nine drug master file entries for this API. Three suppliers are listed for this generic product. Additional details are available on the metformin hydrochloride; saxagliptin hydrochloride profile page.
When can KOMBIGLYZE XR (metformin hydrochloride; saxagliptin hydrochloride) generic drug versions launch?
Generic name: metformin hydrochloride; saxagliptin hydrochloride
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: May 28, 2024
Generic Entry Controlled by: Croatia Patent P20161210
KOMBIGLYZE XR is a drug marketed by Astrazeneca Ab. There are two patents protecting this drug and one Paragraph IV challenge.
This drug has fifty-seven patent family members in thirty-two countries. There has been litigation on patents covering KOMBIGLYZE XR
See drug price trends for KOMBIGLYZE XR.
The generic ingredient in KOMBIGLYZE XR is metformin hydrochloride; saxagliptin hydrochloride. There are forty-nine drug master file entries for this API. Three suppliers are listed for this generic product. Additional details are available on the metformin hydrochloride; saxagliptin hydrochloride profile page.
When can NUCYNTA ER (tapentadol hydrochloride) generic drug versions launch?
Generic name: tapentadol hydrochloride
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: June 28, 2024
Generic Entry Controlled by: Croatia Patent P20110050
NUCYNTA ER is a drug marketed by Collegium Pharm Inc. There are four patents protecting this drug and one Paragraph IV challenge. Three tentatively approved generics are ready to enter the market.
This drug has two hundred and seventy-two patent family members in thirty-one countries. There has been litigation on patents covering NUCYNTA ER
See drug price trends for NUCYNTA ER.
The generic ingredient in NUCYNTA ER is tapentadol hydrochloride. There are five drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the tapentadol hydrochloride profile page.
When can BELVIQ (lorcaserin hydrochloride) generic drug versions launch?
Generic name: lorcaserin hydrochloride
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: December 21, 2024
Generic Entry Controlled by: Croatia Patent P20090640
BELVIQ is a drug marketed by One tentatively approved generic is ready to enter the market.
This drug has two hundred and seventy-two patent family members in thirty-one countries. There has been litigation on patents covering BELVIQ
See drug price trends for BELVIQ.
The generic ingredient in BELVIQ is lorcaserin hydrochloride. There are five drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the lorcaserin hydrochloride profile page.
When can CAPRELSA (vandetanib) generic drug versions launch?
Generic name: vandetanib
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: May 21, 2024
Generic Entry Controlled by: Croatia Patent P20090547
CAPRELSA is a drug marketed by Genzyme Corp. There is one patent protecting this drug.
This drug has forty patent family members in thirty-three countries.
See drug price trends for CAPRELSA.
The generic ingredient in CAPRELSA is vandetanib. One supplier is listed for this generic product. Additional details are available on the vandetanib profile page.
When can CORLANOR (ivabradine hydrochloride) generic drug versions launch?
Generic name: ivabradine hydrochloride
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: February 28, 2025
Generic Entry Controlled by: Croatia Patent P20080520
CORLANOR is a drug marketed by Amgen Inc. There are eight patents protecting this drug. One tentatively approved generic is ready to enter the market.
This drug has ninety-seven patent family members in forty-two countries. There has been litigation on patents covering CORLANOR
See drug price trends for CORLANOR.
The generic ingredient in CORLANOR is ivabradine hydrochloride. There are nine drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the ivabradine hydrochloride profile page.
When can DUTREBIS (lamivudine; raltegravir potassium) generic drug versions launch?
Generic name: lamivudine; raltegravir potassium
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: December 03, 2024
Generic Entry Controlled by: Croatia Patent P20120066
DUTREBIS is a drug marketed by Merck Sharp Dohme. There are two patents protecting this drug.
This drug has ninety-five patent family members in forty-three countries.
The generic ingredient in DUTREBIS is lamivudine; raltegravir potassium. There are twenty-nine drug master file entries for this API. Additional details are available on the lamivudine; raltegravir potassium profile page.
When can NATAZIA (dienogest; estradiol valerate) generic drug versions launch?
Generic name: dienogest; estradiol valerate
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: April 20, 2024
Generic Entry Controlled by: Croatia Patent P20100513
NATAZIA is a drug marketed by Bayer Hlthcare. There are two patents protecting this drug and one Paragraph IV challenge. One tentatively approved generic is ready to enter the market.
This drug has ninety patent family members in thirty-nine countries. There has been litigation on patents covering NATAZIA
See drug price trends for NATAZIA.
The generic ingredient in NATAZIA is dienogest; estradiol valerate. There are seven drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the dienogest; estradiol valerate profile page.
When can NEXAVAR (sorafenib tosylate) generic drug versions launch?
Generic name: sorafenib tosylate
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: March 07, 2025
Generic Entry Controlled by: Croatia Patent P20100674
NEXAVAR is a drug marketed by Bayer Hlthcare. There are two patents protecting this drug and one Paragraph IV challenge.
This drug has eighty-nine patent family members in thirty-nine countries. There has been litigation on patents covering NEXAVAR
See drug price trends for NEXAVAR.
The generic ingredient in NEXAVAR is sorafenib tosylate. There are thirteen drug master file entries for this API. Nine suppliers are listed for this generic product. Additional details are available on the sorafenib tosylate profile page.
When can ONGLYZA (saxagliptin hydrochloride) generic drug versions launch?
Generic name: saxagliptin hydrochloride
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: May 28, 2024
Generic Entry Controlled by: Croatia Patent P20160880
ONGLYZA is a drug marketed by Astrazeneca Ab. There is one patent protecting this drug and one Paragraph IV challenge. One tentatively approved generic is ready to enter the market.
This drug has fifty-seven patent family members in thirty-two countries. There has been litigation on patents covering ONGLYZA
See drug price trends for ONGLYZA.
The generic ingredient in ONGLYZA is saxagliptin hydrochloride. There are fifteen drug master file entries for this API. Six suppliers are listed for this generic product. Additional details are available on the saxagliptin hydrochloride profile page.
When can ONGLYZA (saxagliptin hydrochloride) generic drug versions launch?
Generic name: saxagliptin hydrochloride
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: May 28, 2024
Generic Entry Controlled by: Croatia Patent P20161210
ONGLYZA is a drug marketed by Astrazeneca Ab. There is one patent protecting this drug and one Paragraph IV challenge. One tentatively approved generic is ready to enter the market.
This drug has fifty-seven patent family members in thirty-two countries. There has been litigation on patents covering ONGLYZA
See drug price trends for ONGLYZA.
The generic ingredient in ONGLYZA is saxagliptin hydrochloride. There are fifteen drug master file entries for this API. Six suppliers are listed for this generic product. Additional details are available on the saxagliptin hydrochloride profile page.
When can TYKERB (lapatinib ditosylate) generic drug versions launch?
Generic name: lapatinib ditosylate
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: April 19, 2025
Generic Entry Controlled by: Croatia Patent P20161429
TYKERB is a drug marketed by Novartis. There is one patent protecting this drug and one Paragraph IV challenge.
This drug has twenty-eight patent family members in twenty-six countries.
See drug price trends for TYKERB.
The generic ingredient in TYKERB is lapatinib ditosylate. There are seven drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the lapatinib ditosylate profile page.
When can VITEKTA (elvitegravir) generic drug versions launch?
Generic name: elvitegravir
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: May 20, 2024
Generic Entry Controlled by: Croatia Patent P20120681
VITEKTA is a drug marketed by Gilead Sciences Inc. There are three patents protecting this drug.
This drug has ninety-two patent family members in thirty-six countries. There has been litigation on patents covering VITEKTA
The generic ingredient in VITEKTA is elvitegravir. There are six drug master file entries for this API. Additional details are available on the elvitegravir profile page.
When can XIFAXAN (rifaximin) generic drug versions launch?
Generic name: rifaximin
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: March 03, 2025
Generic Entry Controlled by: Croatia Patent P20070433
XIFAXAN is a drug marketed by Salix Pharms. There are twenty-nine patents protecting this drug and two Paragraph IV challenges. Two tentatively approved generics are ready to enter the market.
This drug has two hundred and eight patent family members in forty countries. There has been litigation on patents covering XIFAXAN
See drug price trends for XIFAXAN.
The generic ingredient in XIFAXAN is rifaximin. There are fourteen drug master file entries for this API. Three suppliers are listed for this generic product. Additional details are available on the rifaximin profile page.
When can VIZIMPRO (dacomitinib) generic drug versions launch?
Generic name: dacomitinib
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: May 06, 2024
Generic Entry Controlled by: Croatia Patent P20110958
VIZIMPRO is a drug marketed by Pfizer. There are four patents protecting this drug.
This drug has ninety-two patent family members in forty-eight countries.
See drug price trends for VIZIMPRO.
The generic ingredient in VIZIMPRO is dacomitinib. Two suppliers are listed for this generic product. Additional details are available on the dacomitinib profile page.
When can AEMCOLO (rifamycin) generic drug versions launch?
Generic name: rifamycin
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: June 25, 2024
Generic Entry Controlled by: Croatia Patent P20080252
AEMCOLO is a drug marketed by Redhill. There are four patents protecting this drug.
This drug has twenty-eight patent family members in twenty-one countries.
See drug price trends for AEMCOLO.
The generic ingredient in AEMCOLO is rifamycin. There are eleven drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the rifamycin profile page.
When can CORLANOR (ivabradine) generic drug versions launch?
Generic name: ivabradine
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: February 28, 2025
Generic Entry Controlled by: Croatia Patent P20080406
CORLANOR is a drug marketed by Amgen Inc. There are eight patents protecting this drug. One tentatively approved generic is ready to enter the market.
This drug has ninety-seven patent family members in forty-two countries. There has been litigation on patents covering CORLANOR
See drug price trends for CORLANOR.
The generic ingredient in CORLANOR is ivabradine. There are nine drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the ivabradine profile page.
When can WAKIX (pitolisant hydrochloride) generic drug versions launch?
Generic name: pitolisant hydrochloride
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: February 10, 2025
Generic Entry Controlled by: Croatia Patent P20080446
WAKIX is a drug marketed by Harmony. There are three patents protecting this drug.
This drug has sixty-one patent family members in thirty-one countries. There has been litigation on patents covering WAKIX
See drug price trends for WAKIX.
The generic ingredient in WAKIX is pitolisant hydrochloride. One supplier is listed for this generic product. Additional details are available on the pitolisant hydrochloride profile page.
When can VYONDYS 53 (golodirsen) generic drug versions launch?
Generic name: golodirsen
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: June 28, 2024
Generic Entry Controlled by: Croatia Patent P20110352
VYONDYS 53 is a drug marketed by Sarepta Theraps Inc. There are eight patents protecting this drug.
This drug has thirty patent family members in thirteen countries. There has been litigation on patents covering VYONDYS 53
The generic ingredient in VYONDYS 53 is golodirsen. One supplier is listed for this generic product. Additional details are available on the golodirsen profile page.
When can VYONDYS 53 (golodirsen) generic drug versions launch?
Generic name: golodirsen
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: June 28, 2024
Generic Entry Controlled by: Croatia Patent P20160225
VYONDYS 53 is a drug marketed by Sarepta Theraps Inc. There are eight patents protecting this drug.
This drug has thirty patent family members in thirteen countries. There has been litigation on patents covering VYONDYS 53
The generic ingredient in VYONDYS 53 is golodirsen. One supplier is listed for this generic product. Additional details are available on the golodirsen profile page.
When can KOSELUGO (selumetinib sulfate) generic drug versions launch?
Generic name: selumetinib sulfate
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: December 21, 2025
Generic Entry Controlled by: Croatia Patent P20130663
KOSELUGO is a drug marketed by Astrazeneca. There are five patents protecting this drug.
This drug has one hundred and ninety-eight patent family members in forty-four countries.
See drug price trends for KOSELUGO.
The generic ingredient in KOSELUGO is selumetinib sulfate. One supplier is listed for this generic product. Additional details are available on the selumetinib sulfate profile page.
When can YONDELIS (trabectedin) generic drug versions launch?
Generic name: trabectedin
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: October 29, 2024
Generic Entry Controlled by: Croatia Patent P20070374
YONDELIS is a drug marketed by Janssen Prods. There is one patent protecting this drug. One tentatively approved generic is ready to enter the market.
This drug has forty-four patent family members in thirty-six countries. There has been litigation on patents covering YONDELIS
See drug price trends for YONDELIS.
The generic ingredient in YONDELIS is trabectedin. There are four drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the trabectedin profile page.
When can FOLOTYN (pralatrexate) generic drug versions launch?
Generic name: pralatrexate
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: May 30, 2024
Generic Entry Controlled by: Croatia Patent P20080569
FOLOTYN is a drug marketed by Acrotech Biopharma. There are two patents protecting this drug and one Paragraph IV challenge. One tentatively approved generic is ready to enter the market.
This drug has thirty-one patent family members in twenty-three countries. There has been litigation on patents covering FOLOTYN
See drug price trends for FOLOTYN.
The generic ingredient in FOLOTYN is pralatrexate. There are two drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the pralatrexate profile page.
When can TARGINIQ (naloxone hydrochloride; oxycodone hydrochloride) generic drug versions launch?
Generic name: naloxone hydrochloride; oxycodone hydrochloride
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: March 30, 2024
Generic Entry Controlled by: Croatia Patent P20110425
TARGINIQ is a drug marketed by Purdue Pharma Lp. There are two patents protecting this drug.
This drug has one hundred and fifty-one patent family members in forty-one countries. There has been litigation on patents covering TARGINIQ
The generic ingredient in TARGINIQ is naloxone hydrochloride; oxycodone hydrochloride. There are twelve drug master file entries for this API. Additional details are available on the naloxone hydrochloride; oxycodone hydrochloride profile page.
When can TARGINIQ (naloxone hydrochloride; oxycodone hydrochloride) generic drug versions launch?
Generic name: naloxone hydrochloride; oxycodone hydrochloride
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: March 30, 2024
Generic Entry Controlled by: Croatia Patent P20150358
TARGINIQ is a drug marketed by Purdue Pharma Lp. There are two patents protecting this drug.
This drug has one hundred and fifty-one patent family members in forty-one countries. There has been litigation on patents covering TARGINIQ
The generic ingredient in TARGINIQ is naloxone hydrochloride; oxycodone hydrochloride. There are twelve drug master file entries for this API. Additional details are available on the naloxone hydrochloride; oxycodone hydrochloride profile page.
When can TARGINIQ (naloxone hydrochloride; oxycodone hydrochloride) generic drug versions launch?
Generic name: naloxone hydrochloride; oxycodone hydrochloride
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: March 30, 2024
Generic Entry Controlled by: Croatia Patent P20160223
TARGINIQ is a drug marketed by Purdue Pharma Lp. There are two patents protecting this drug.
This drug has one hundred and fifty-one patent family members in forty-one countries. There has been litigation on patents covering TARGINIQ
The generic ingredient in TARGINIQ is naloxone hydrochloride; oxycodone hydrochloride. There are twelve drug master file entries for this API. Additional details are available on the naloxone hydrochloride; oxycodone hydrochloride profile page.
When can TARGINIQ (naloxone hydrochloride; oxycodone hydrochloride) generic drug versions launch?
Generic name: naloxone hydrochloride; oxycodone hydrochloride
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: March 30, 2024
Generic Entry Controlled by: Croatia Patent P20160885
TARGINIQ is a drug marketed by Purdue Pharma Lp. There are two patents protecting this drug.
This drug has one hundred and fifty-one patent family members in forty-one countries. There has been litigation on patents covering TARGINIQ
The generic ingredient in TARGINIQ is naloxone hydrochloride; oxycodone hydrochloride. There are twelve drug master file entries for this API. Additional details are available on the naloxone hydrochloride; oxycodone hydrochloride profile page.
When can TARGINIQ (naloxone hydrochloride; oxycodone hydrochloride) generic drug versions launch?
Generic name: naloxone hydrochloride; oxycodone hydrochloride
DrugPatentWatch® Estimated Patent Expiration / Generic Entry Opportunity Date: March 30, 2024
Generic Entry Controlled by: Croatia Patent P20180407
TARGINIQ is a drug marketed by Purdue Pharma Lp. There are two patents protecting this drug.
This drug has one hundred and fifty-one patent family members in forty-one countries. There has been litigation on patents covering TARGINIQ
The generic ingredient in TARGINIQ is naloxone hydrochloride; oxycodone hydrochloride. There are twelve drug master file entries for this API. Additional details are available on the naloxone hydrochloride; oxycodone hydrochloride profile page.
DrugPatentWatch cited by CNN, NEJM, Nature Journals, and more …
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.